We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
+117.73%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.51B
AUM Growth
+$863M
Cap. Flow
-$27.8M
Cap. Flow %
-1.11%
Top 10 Hldgs %
46.81%
Holding
87
New
12
Increased
10
Reduced
29
Closed
20

Top Buys

Rank Stock Value
1
VIE
Viela Bio, Inc. Common Stock
VIE
+$37.7M
2
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$31.4M
3
ZYME icon
Zymeworks
ZYME
+$25.4M
4
CABA icon
Cabaletta Bio
CABA
+$25.1M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$24.2M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.6M
2
QURE icon
uniQure
QURE
+$27.5M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$16.1M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.9M
5
ALLK
Allakos
ALLK
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 84.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
51
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
$9.89M 0.39%
+250,000
New +$4.39M
HARP
52
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$9.61M 0.38%
64,999
– –
ARNA
53
DELISTED
Arena Pharmaceuticals Inc
ARNA
$7.83M 0.31%
172,300
– –
DTIL icon
54
Precision BioSciences
DTIL
$193M
$6.49M 0.26%
15,584
– –
TECX
55
Tectonic Therapeutic
TECX
$558M
$6.39M 0.26%
26,465
-20,893
-44% -$4.03M
AUTL
56
Autolus Therapeutics
AUTL
$506M
$6.34M 0.25%
479,988
– –
IGMS
57
DELISTED
IGM Biosciences
IGMS
$5.97M 0.24%
156,400
– –
ANAB icon
58
AnaptysBio
ANAB
$1.63B
$5.93M 0.24%
365,000
-226,200
-38% -$5.35M
BCEL
59
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$5.04M 0.2%
326,141
-80,001
-20% -$966K
ORTX
60
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.82M 0.19%
35,020
-32,513
-48% -$3.95M
GOSS icon
61
Gossamer Bio
GOSS
$86.9M
$4.69M 0.19%
300,000
-318,129
-51% -$6.41M
NERV icon
62
Minerva Neurosciences
NERV
$203M
$4.32M 0.17%
75,988
– –
NKTR icon
63
Nektar Therapeutics
NKTR
$2.47B
$4.32M 0.17%
13,333
-39,254
-75% -$11.4M
NBIX icon
64
Neurocrine Biosciences
NBIX
$16.4B
$4.22M 0.17%
39,300
– –
XFOR icon
65
X4 Pharmaceuticals
XFOR
$391M
$2.7M 0.11%
8,425
-20,964
-71% -$7.52M
TBPH icon
66
Theravance Biopharma
TBPH
$876M
$1.29M 0.05%
+50,000
New +$972K
OTLKW
67
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$27K ﹤0.01%
416,666
– –
ABEO icon
68
Abeona Therapeutics
ABEO
$388M
– –
-8,000
Closed -$452K
ACRS icon
69
Aclaris Therapeutics
ACRS
$888M
– –
-250,000
Closed -$270K
ADVM
70
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-30,000
Closed -$1.64M
ATRA icon
71
Atara Biotherapeutics
ATRA
$76.9M
– –
-12,000
Closed -$4.24M
GNFT
72
DELISTED
Genfit
GNFT
– –
-300,000
Closed -$5.22M
IFRX icon
73
InflaRx
IFRX
$261M
– –
-300,000
Closed -$741K
ITRM
74
DELISTED
Iterum Therapeutics
ITRM
– –
-26,426
Closed -$2.34M
KZR
75
DELISTED
Kezar Life Sciences
KZR
– –
-92,787
Closed -$3.04M
1 2
3
4

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q4 2019 Portfolio in Review

As of Q4 2019, Cormorant Asset Management held 87 positions worth $2.51B, up 53% from $1.64B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Cormorant Asset Management's Q4 2019 filing shows 12 new, 10 increased, 29 reduced and 20 closed positions. Its largest new stake was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier.

  • Cormorant Asset Management's largest Q4 2019 buy was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M.
  • Cormorant Asset Management added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $31.4M increase.
  • Cormorant Asset Management's biggest Q4 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.6M.
  • Cormorant Asset Management fully exited Sage Therapeutics in Q4 2019, selling an estimated $12.4M.
  • Cormorant Asset Management's ten largest holdings make up 47% of its $2.51B portfolio in Q4 2019.
  • Cormorant Asset Management opened 12 new positions and closed 20 in Q4 2019.
  • Cormorant Asset Management's portfolio value rose 53% quarter-over-quarter to $2.51B.

Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.